Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label …

…, T Kato, T Hara, K Hamaoka, S Ogawa, M Miura… - The Lancet, 2012 - thelancet.com
Background Evidence indicates that corticosteroid therapy might be beneficial for the primary
treatment of severe Kawasaki disease. We assessed whether addition of prednisolone to …

A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population

…, S Matsuda, K Sekine, S Kondo, M Miura… - Journal of the American …, 2016 - Elsevier
Background Several coronary artery Z score models have been developed. However, a Z
score model derived by the lambda-mu-sigma (LMS) method has not been established. …

Association of severity of coronary artery aneurysms in patients with Kawasaki disease and risk of later coronary events

M Miura, T Kobayashi, T Kaneko, M Ayusawa… - JAMA …, 2018 - jamanetwork.com
Importance Few studies with sufficient statistical power have shown the association of
thezscore of the coronary arterial internal diameter with coronary events (CE) in patients with …

Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study

…, O Komiyama, H Yamagishi, M Miura - The Lancet Child & …, 2018 - thelancet.com
Background The RAISE study showed that additional prednisolone improved coronary artery
outcomes in patients with Kawasaki disease at high risk of intravenous immunoglobulin (…

JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease

…, J Kobayashi, M Ayusawa, H Hamada, M Miura… - Circulation …, 2020 - jstage.jst.go.jp
More than 50 years have passed since Kawasaki disease (KD) was first reported. 1 According
to a nationwide survey, the number of patients with KD who became adults was 136,960 …

Revision of diagnostic guidelines for Kawasaki disease .

…, H Matsuura, T Matsubara, M Miura… - Pediatrics …, 2020 - search.ebscohost.com
The article discusses the sixth revised diagnostic guidelines for Kawasaki disease (KD)
among children in Japan. The revisions from the fifth guidelines include fever duration to five …

JCS 2018 guideline on diagnosis of chronic coronary heart diseases

…, A Nohara, A Hirayama, N Funabashi, M Miura… - Circulation …, 2021 - jstage.jst.go.jp
Objectives”, explains how to select and use various test methods for evaluating disease
states, the prognosis, and the effects of treatment. References to the literature published since …

[HTML][HTML] Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for …

…, S Ohno, H Itoh, A Takeuchi, S Matsuoka, M Miura… - PLoS …, 2016 - journals.plos.org
Introduction Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for
disease modeling. However, it is not invariably successful to recapitulate the disease …

Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease

…, T Saji, T Sonobe, S Ogawa, M Miura… - The Pediatric …, 2009 - journals.lww.com
Background: We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone
for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (…

Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis

K Tanaka, H Shimada, M Miura, Y Fujii… - World journal of …, 2004 - Springer
We determined the relative value of the metastatic colorectal cancer doubling time as a
predictor of recurrence and survival after hepatectomy in comparison with other established …